H K Kroemer

3.1k total citations
50 papers, 1.4k citations indexed

About

H K Kroemer is a scholar working on Pharmacology, Molecular Biology and Oncology. According to data from OpenAlex, H K Kroemer has authored 50 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pharmacology, 15 papers in Molecular Biology and 14 papers in Oncology. Recurrent topics in H K Kroemer's work include Pharmacogenetics and Drug Metabolism (17 papers), Drug Transport and Resistance Mechanisms (9 papers) and Pharmaceutical studies and practices (5 papers). H K Kroemer is often cited by papers focused on Pharmacogenetics and Drug Metabolism (17 papers), Drug Transport and Resistance Mechanisms (9 papers) and Pharmaceutical studies and practices (5 papers). H K Kroemer collaborates with scholars based in Germany, United States and France. H K Kroemer's co-authors include Michel Eichelbaum, Ulrich Klotz, Gerd Mikus, Gabriele Jedlitschky, Markus Grube, Thomas E. Mürdter, Bernhard Sperker, Stefan Oswald, Werner Siegmund and Dan M. Roden and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Neuroscience.

In The Last Decade

H K Kroemer

50 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H K Kroemer Germany 25 371 337 336 223 169 50 1.4k
Kirstin Thelen Germany 20 324 0.9× 191 0.6× 386 1.1× 259 1.2× 156 0.9× 26 1.3k
Yuji Kumagai Japan 25 412 1.1× 493 1.5× 254 0.8× 261 1.2× 230 1.4× 127 2.0k
Ophelia Yin United States 28 647 1.7× 433 1.3× 441 1.3× 261 1.2× 247 1.5× 94 2.3k
Stefan Russmann Switzerland 26 276 0.7× 263 0.8× 499 1.5× 208 0.9× 125 0.7× 64 2.2k
Atilla Bozkurt Türkiye 21 239 0.6× 243 0.7× 420 1.3× 226 1.0× 100 0.6× 94 1.6k
Barbara Ameer United States 20 238 0.6× 249 0.7× 547 1.6× 216 1.0× 160 0.9× 42 1.9k
Kyoung Soo Lim South Korea 22 396 1.1× 255 0.8× 352 1.0× 237 1.1× 152 0.9× 84 1.5k
Peter H. Hinderling United States 19 189 0.5× 252 0.7× 200 0.6× 131 0.6× 187 1.1× 48 1.1k
Huy Riêm Ha Switzerland 16 482 1.3× 246 0.7× 504 1.5× 249 1.1× 93 0.6× 21 1.3k
Young‐Ran Yoon South Korea 21 280 0.8× 516 1.5× 344 1.0× 85 0.4× 123 0.7× 96 1.3k

Countries citing papers authored by H K Kroemer

Since Specialization
Citations

This map shows the geographic impact of H K Kroemer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H K Kroemer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H K Kroemer more than expected).

Fields of papers citing papers by H K Kroemer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H K Kroemer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H K Kroemer. The network helps show where H K Kroemer may publish in the future.

Co-authorship network of co-authors of H K Kroemer

This figure shows the co-authorship network connecting the top 25 collaborators of H K Kroemer. A scholar is included among the top collaborators of H K Kroemer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H K Kroemer. H K Kroemer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Keiser, Markus, Stefan Oswald, Gabriele Jedlitschky, et al.. (2016). Expression of Organic Anion Transporting Polypeptide 1A2 in Red Blood Cells and Its Potential Impact on Antimalarial Therapy. Drug Metabolism and Disposition. 44(10). 1562–1568. 16 indexed citations
2.
Ameling, Sabine, Elke Hammer, Sebastian Herzog, et al.. (2012). Regulation of Interferon-Inducible Proteins by Doxorubicin via Interferon γ-Janus Tyrosine Kinase-Signal Transducer and Activator of Transcription Signaling in Tumor Cells. Molecular Pharmacology. 81(5). 679–688. 22 indexed citations
3.
Laufs, Ulrich, et al.. (2011). Strategien zur Verbesserung der Einnahmetreue von Medikamenten. DMW - Deutsche Medizinische Wochenschrift. 136(31/32). 1616–1621. 24 indexed citations
4.
Rosskopf, Dieter, Christian Schwahn, F. Neumann, et al.. (2010). The growth hormone—IGF-I axis as a mediator for the association between FTO variants and body mass index: results of the Study of Health in Pomerania. International Journal of Obesity. 35(3). 364–372. 17 indexed citations
5.
Bien, Sandra, Christian Rimmbach, Hans Neumann, et al.. (2010). Doxorubicin-induced cell death requires cathepsin B in HeLa cells. Biochemical Pharmacology. 80(10). 1466–1477. 24 indexed citations
6.
Donat, Ulrike, et al.. (2008). Vardenafil protects isolated rat hearts at reperfusion dependent on GC and PKG. British Journal of Pharmacology. 154(1). 25–31. 26 indexed citations
7.
Dazert, Peter, Yalikun Suofu, Markus Grube, et al.. (2006). Differential regulation of transport proteins in the periinfarct region following reversible middle cerebral artery occlusion in rats. Neuroscience. 142(4). 1071–1079. 51 indexed citations
8.
Meisel, Peter, J. Giebel, Christiane Kunert‐Keil, et al.. (2006). MDR1 gene polymorphisms and risk of gingival hyperplasia induced by calcium antagonists. Clinical Pharmacology & Therapeutics. 79(1). 62–71. 30 indexed citations
9.
Hoppe, Uta C., Michael Böhm, Rainer Dietz, et al.. (2005). Leitlinien zur Therapie der chronischen Herzinsuffizienz. Zeitschrift für Kardiologie. 94(8). 488–509. 68 indexed citations
10.
Meissner, Konrad, et al.. (2000). Arzneimittelinteraktionen: Neue Mechanismen und klinische Relevanz. Der Internist. 41(4). 338–343. 3 indexed citations
11.
Mürdter, Thomas E., A. Linder, Godehard Friedel, et al.. (2000). Pharmakokinetik von Cyclo-phosphamid, Adriamycin und Adramycin-Prodrug (HMR 1826) im ex-vivo-isolierten perfundierten humanen Lungenresektionsmodell (IHLP)1. Pneumologie. 54(11). 494–498. 5 indexed citations
12.
Fritz, Péter, Bernhard Sperker, Thomas E. Mürdter, et al.. (1999). Quantitative immunohistochemical analysis of the glutathione S-transferase GSTM1: in situ phenotyping in archival material. Xenobiotica. 29(7). 693–702. 4 indexed citations
13.
Busse, Dagmar, H K Kroemer, Bernhard Sperker, & Thomas E. Mürdter. (1998). Fortschritte in der Therapie von Tumorerkrankungen mit Zytostatika: Untersuchungen zur Hochdosistherapie mit Cyclophosphamid und zum Drug Targeting von Doxorubicin. Pharmazie in unserer Zeit. 27(5). 216–222. 1 indexed citations
14.
Busse, Dagmar, F.W. Busch, Frank Bohnenstengel, et al.. (1997). Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism.. Journal of Clinical Oncology. 15(5). 1885–1896. 91 indexed citations
15.
16.
17.
Heinkele, Georg, et al.. (1994). Rapid determination of CYP2D6 phenotype during propafenone therapy by analysing urinary excretion of propafenone glucuronides. European Journal of Clinical Pharmacology. 46(2). 133–5. 10 indexed citations
18.
Eichelbaum, Michel, H K Kroemer, & Gerd Mikus. (1992). Genetically determined differences in drug metabolism as a risk factor in drug toxicity. Toxicology Letters. 64-65. 115–122. 48 indexed citations
19.
Mikus, Gerd, Michel Eichelbaum, Christine Fischer, et al.. (1990). Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action.. Journal of Pharmacology and Experimental Therapeutics. 253(3). 1042–1048. 57 indexed citations
20.
Klotz, Ulrich, P. Arvela, Markku Pasanen, H K Kroemer, & Olavi Pelkonen. (1987). Comparative effects of H2-receptor antagonists on drug metabolism in vitro and in vivo. Pharmacology & Therapeutics. 33(1). 157–162. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kirstin Thelen Breakdown of academic impact, for papers by Yuji Kumagai Breakdown of academic impact, for papers by Ophelia Yin Breakdown of academic impact, for papers by Stefan Russmann Breakdown of academic impact, for papers by Atilla Bozkurt Breakdown of academic impact, for papers by Barbara Ameer Breakdown of academic impact, for papers by Kyoung Soo Lim Breakdown of academic impact, for papers by Peter H. Hinderling Breakdown of academic impact, for papers by Huy Riêm Ha Breakdown of academic impact, for papers by Young‐Ran Yoon
Rankless by CCL
2026